{"id":36123,"date":"2023-08-22T20:59:03","date_gmt":"2023-08-22T18:59:03","guid":{"rendered":"https:\/\/www.ipsen.com\/press-releases\/la-commission-europeenne-approuve-cabometyx-en-association-avec-opdivo-comme-traitement-de-premiere-ligne-pour-les-patients-atteints-dun-carcinome-du-rein-avance\/"},"modified":"2024-08-09T07:36:11","modified_gmt":"2024-08-09T05:36:11","slug":"la-commission-europeenne-approuve-cabometyx-en-association-avec-opdivo-comme-traitement-de-premiere-ligne-pour-les-patients-atteints-dun-carcinome-du-rein-avance-2","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/fr\/press-releases\/la-commission-europeenne-approuve-cabometyx-en-association-avec-opdivo-comme-traitement-de-premiere-ligne-pour-les-patients-atteints-dun-carcinome-du-rein-avance-2\/","title":{"rendered":"La Commission europ\u00e9enne approuve Cabometyx\u00ae en association avec Opdivo\u00ae comme traitement de premi\u00e8re ligne pour les patients atteints d\u2019un carcinome du rein avanc\u00e9"},"content":{"rendered":"